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Background: Acceptable post-orchiectomy adjuvant therapy strategies for stage I seminoma 
patients include surveillance, para-aortic radiation therapy (RT), dog-leg RT, and a single 
cycle of carboplatin. The required follow-up recommendations were amended by the National 
Comprehensive Cancer Network (NCCN) in 2012. Given a cause-specific survival of nearly 
100%, a closer analysis of the reimbursement for each treatment strategy is warranted.
Methods: NCCN guidelines were used to design treatment plans for each acceptable adjuvant 
treatment strategy. Follow-up charges were generated for 10 years based on 2012 (version 1.2012; 
unchanged in current version 1.2013) and 2011 NCCN (version 2.2011) surveillance 
recommendations. The 2012 Medicare reimbursement rates were used to calculate each treatment 
strategy and incremental cost-effectiveness ratios to compare the treatment options.
Results: Under the current NCCN follow-up recommendations, the total reimbursements gener-
ated over 10 years of surveillance, para-aortic RT, dog-leg RT, and carboplatin were $10,643, 
$11,678, $9,662, and $10,405, respectively. This is compared with the reimbursements as per the 
2011 NCCN recommendations: $20,986, $11,517, $9,394, and $20,365 respectively. Factoring 
the rates of relapse into a salvage model, observation was found to be more costly and less effec-
tive ($–1,831, $−7,318, $–7,010) in the adjuvant management of stage I seminoma patients.
Conclusion: Based on incremental cost-effectiveness ratios, para-aortic RT, dog-leg RT, and 
carboplatin are cost-effective options for the treatment of stage I seminoma when compared 
with observation; however, surveillance could potentially spare as many as 80%–85% of men 
diagnosed with stage I seminoma from additional therapy after radical inguinal orchiectomy. 
Such cost and reimbursement analyses are becoming increasingly relevant, but are not meant to 
usurp sound clinical judgment. Further studies are required to validate these findings.
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Introduction
Testicular seminoma is the most common malignancy in men aged 15–35 years.1 Stage I 
seminoma patients are initially treated by radical inguinal orchiectomy. Orchiectomy 
is both diagnostic as well as therapeutic; however, surgical management alone results 
in relapse rates as high as 20% at 15 years,2 with most relapses identified in the para-
aortic lymph nodes.3 Nonetheless, disease-specific survival for patients with stage I 
seminoma approaches 100%.2,4 This excellent outcome is related to the effectiveness 
of salvage therapies, either chemotherapy-based or radiation-based, as pure seminoma 
tumors display high rates of sensitivity to chemotherapy and radiation therapy (RT).
Concerns about long-term side effects, such as infertility and second malignan-
cies, given this near zero cancer-specific mortality rate, have led to migration away 





from the historical adjuvant standard of care, which has been 
post-orchiectomy RT, despite reductions of 5-year relapse 
rates with RT.5–7 Reduced field size and total dose have not 
overcome these concerns.4,8–10 Surveillance alone arose as an 
alternative, given the opportunity to spare 80%–85% of young 
men the potential treatment-related adverse events seen with 
adjuvant RT. Acceptable outcomes were noted in single-arm 
surveillance alone cohort studies and a pooled analysis.2,3,11–13 
More recently, post-orchiectomy chemotherapy has emerged 
as an accepted alternative.14,15 The Medical Research  Council 
TE 19/EORTC 30982 noninferiority randomized trial com-
paring single-dose carboplatin with adjuvant RT, with a 
median follow-up of 6.5 years, confirmed the noninferiority 
of single-dose carboplatin compared with RT.15
Currently, the three acceptable treatment options for 
patients with stage I seminoma following orchiectomy 
(National Comprehensive Cancer Network [NCCN] guide-
lines 1.2013) are surveillance alone, chemotherapy with 
single-agent carboplatin, or RT to the para-aortic nodes with 
or without irradiation of the ipsilateral pelvic nodes (dog-
leg technique). All three recommendations are considered 
category 1 recommendations by the panel and specifically 
state intervention is appropriate. However, the NCCN panel 
suggests that for stage I disease with pT1 and pT2 tumors 
and that do not involve the spermatic cord, that surveillance 
is the “preferred” treatment recommendation. Further, the 
surveillance strategy, including posttreatment follow-up 
recommendations, was significantly attenuated from previ-
ous guidelines.
In 2012, the NCCN significantly altered their follow-up 
recommendations for surveillance as well as post-adjuvant 
treatment imaging. Imaging is a significant cost in the follow-
up management of seminoma. Indeed, it is the primary cost in 
the setting of surveillance as well as posttreatment follow-up. 
Previous reports have evaluated the cost of adjuvant manage-
ment strategies in the setting of stage I seminoma.16,17 More 
recently, Kollmannsberger et al have recommended that only 
a computed tomography (CT) scan of the abdomen is needed 
while abandoning the pelvic part of the CT.18 We postulated 
that the guideline changes would have significant reverbera-
tions in the overall cost analysis of each strategy.
In light of the NCCN changes decreasing the follow-up 
burden on all post-orchiectomy strategies, we sought to read-
dress the cost analysis of adjuvant management options in 
patients with stage I seminoma. Indeed, cost is among the rea-
sons cited by physicians to recommend adjuvant treatment.19 
We assessed the reimbursement cost associated with each 
modality given the changing thought processes of oncologic 
physicians caring for these young patients, as highlighted 
by the recent NCCN guideline changes. Such changes have 
significant implications with respect to cost-effectiveness of 
seemly equivalent management strategies that are likely to 
become more germane to the evolving health care landscape 
in the USA and abroad.
Materials and methods
Key assumptions for model
The purpose of this study was to assess the changes in the 
NCCN guidelines for stage I seminoma and evaluate the 
costs associated with those recommendations. The NCCN 
guidelines from 2011 and 2012 were used to design post-
orchiectomy treatment plans for each of the acceptable 
adjuvant treatment strategies: surveillance alone, single-
agent carboplatin (area under the concentration–time curve 
=7), para-aortic RT (20 Gy), dog-leg field RT (20 Gy), and 
salvage chemotherapy (bleomycin, etoposide and cisplatin 
[BEP], three cycles). BEP salvage chemotherapy for three 
cycles was assumed as the default salvage regimen for relapse 
in each adjuvant management strategy. This assumption 
excludes salvage RT, which would be considered standard 
of care in the relapsed staging equivalent of stage IIA or 
IIB for patients who elected for initial active surveillance or 
carboplatin and failed on a para-aortic or pelvic distribution 
alone.20–23 This assumption simplified the comparison for 
each management strategy. NCCN guidelines for growth 
factor support and antiemetic use were incorporated into the 
treatments. Follow-up charges, including weighted costs for 
salvage using each modality, were generated for 10 years 
based on both the 2012 and 2011 NCCN guidelines. Accord-
ing to the published literature,15 the anticipated failure rate 
assumed for surveillance alone, either dog-leg RT or para-
aortic RT, or carboplatin was 18%, 4%, and 5% respectively. 
Three assumptions were made for creation of the relapse 
and salvage BEP costs for our reimbursement models, ie, 
no patients relapsed after 5 years, no patients were lost to 
follow-up, and no patients had early relapse.
NccN guidelines
The NCCN, a not-for-profit alliance of 23 of the world’s 
leading cancer centers, is dedicated to improving the quality 
and effectiveness of care provided to patients with cancer. 
In 2012, the NCCN changed the follow-up criteria for post-
orchiectomy patients due to a number of findings as discussed 
above (these follow-up changes are still current as per the 
most recent version, 1.2013). These changes were based on 
data from the Medical Research Council TE/EORTC 30982 
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study that was recently published and new information 
regarding the potential of excess radiation exposure with 
additional imaging tests. With that information in hand, 
the NCCN issued new recommendations for follow-up and 
surveillance for each adjuvant option. These changes are 
reflected in Tables 1 and 2.
cost
The reimbursement and facility cost-effectiveness was 
evaluated with reimbursement models based on 2012 and 
2011 Medicare reimbursement fee schedules for facility 
and professional charges generated based on International 
Classification of Diseases 9th Edition codes for carboplatin, 
RT, and salvage BEP. Although Medicare would not be the 
primary insurance provider for this patient population, it was 
the most consistent source that could be used in order to con-
duct the analysis given that reimbursement information for 
private insurance carriers varies between each hospital (and 
state). The treatment regimens for each modality were based 
on the 2012 NCCN guidelines for treatment and management 
of stage I seminoma. The recommended follow-up schedules 
were also based on the NCCN guidelines for 2011 and 2012 
(these represent the current working guidelines to date, with 
no interval changes since study initiation, version 1.2013).
incremental cost-effectiveness ratio
Cost-effectiveness analyses were performed using incremen-
tal cost-effectiveness ratios (ICERs), which were calculated 
based on the ratio of the difference in reimbursement to the 
criteria being evaluated. By using this ratio, comparisons can 
be made between treatment modalities for specific diseases 
to determine a most cost-effective strategy, thus providing 
an opportunity to contain costs without jeopardizing patient 
care. For the ICER analysis, 5-year relapse-free survival 
was used to compare the outcomes of the different treatment 
modalities for first-line treatment and salvage therapy. The 
ICER is calculated by taking the cost of modalities (ie, reim-
bursement) and the parameter (eg, 5-year relapse-free rate) in 
question and using the following equation: ICER = (A reim-
bursement – B reimbursement)/(A outcome – B outcome) = $ 
per percent improvement when comparing modality A with 
modality B. The value returned provides a dollar amount per 
percent improvement in the parameter being evaluated. For 
our purposes, surveillance was the parameter being evalu-
ated with the ICER calculation. A limitation of this analysis 
is that when a modality costs less and has better outcomes, 
negative numbers are returned as no incremental benefit to 
increased cost is being observed.
Results
Descriptive reimbursement rates 
comparing NccN 2011 versus 2012 
follow-up recommendations
Significant reimbursement cost savings for patients given 
adjuvant carboplatin or surveillance alone in 2012 were noted 
compared with patients with 10-year follow-up recommen-
dations as per 2011 NCCN guidelines. The reimbursement 
costs, when comparing treatments costs and follow-up costs 
between 2011 and 2012, were essentially unchanged for both 
para-aortic RT or dog-leg RT. 





e&M expanded/low MDM PF 20 14
ct abdomen and pelvis with contrast 20 7
Alpha-fetoprotein 20 14
Lactate dehydrogenase 20 14
Human chorionic gonadotropin 20 14
Single-agent carboplatin
e&M expanded/low MDM PF 20 16
ct abdomen and pelvis with contrast 20 3
Alpha-fetoprotein 20 16
Lactate dehydrogenase 20 16
Human chorionic gonadotropin 20 16
RT (PA nodes only)
e&M expanded/low MDM PF 13 14
ct abdomen and pelvis with contrast 3 3
Alpha-fetoprotein 14 14
Lactate dehydrogenase 14 14
Human chorionic gonadotropin 14 14
RT (dog-leg)
e&M expanded/low MDM PF 13 14
ct abdomen and pelvis with contrast 0 0
Alpha-fetoprotein 13 14
Lactate dehydrogenase 13 14
Human chorionic gonadotropin 13 14
Abbreviations: ct, computed tomography; e&M, evaluation and management; MDM, 
medical decision making; PA, para-aortic; PF, patient follow-up; Rt, radiotherapy.
Table 2 treatment and follow-up reimbursement comparison 
between 2011 and 2012
Adjuvant  
strategy








Abbreviations: DL, dog-leg; PA, para-aortic; Rt, radiation therapy.





Relapse and salvage BeP  
reimbursement model
Factoring the costs of salvage BEP for three cycles after 
relapse, a salvage reimbursement model was created. Using 
the 2011 and 2012 frequency of follow-up imaging, physical 
examinations, and laboratory markers (Tables 3 and 4), sig-
nificant savings are encountered in year-by-year comparison 
of surveillance alone and adjuvant carboplatin. The reduced 
follow-up imaging, examinations, and markers required for 
surveillance and adjuvant carboplatin management as per the 
2012 guidelines provided a greater than 50% reduction in 
reimbursement costs as per our salvage model. As expected, 
para-aortic RT and dog-leg RT reimbursement costs differed 
little in our salvage reimbursement model when comparing 
2011 with 2012.
 Alternative relapse and salvage  
BeP reimbursement model
Looking critically at the model for our calculations above, 
we assumed that 18% (managed by surveillance), 5% 
(managed by adjuvant chemotherapy), and 4% (either 
adjuvant RT strategy) of patients will relapse at 5 years. 
No patients were assumed to have relapsed after 5 years. 
Kollmannsberger et al24 reported median relapse times of 
14 months, 14.5 months, and 20 months for patients man-
aged with surveillance, RT, or carboplatin, respectively. 
This discredits our original hypothetical model and led us to 
worry about a potential large overestimation of the accrued 
reimbursement figures for follow-up examinations, markers, 
and CT-based imaging. Therefore, we modeled a separate 
relapse model where the relapse timeframe would be a 
weighted model where 80% of patients who relapse would 
have their initial relapse at 12 months, 15% would relapse 
at 30 months, and 5% would not relapse until 5 years. This 
weighted salvage model showed a reimbursement change 
from the 2011 to 2012 NCCN guidelines for each modality: 
surveillance alone ($12,916.06 to $8,518.12), carboplatin 
($12,413.35 to $5,437.60), para-aortic RT ($4,556.06 to 
$4,815.63), and dog-leg RT ($2,583.49 to $2,843.04). The 
comparison of these two groups (2011 versus 2012), treated 
as a normal distribution, was found not to be statistically sig-
nificant (P=0.228), using Student’s t-test analysis. This crude 
weighted model shows that even when considering early 
relapse, the greatest cost is associated with salvage BEP.
iceR with and without factoring salvage
ICER analysis comparing the reimbursement costs without 
factoring in a salvage or relapse model, using surveillance 
as the evaluated parameter and 5-year relapse-free survival 
rate as the outcome, found surveillance to be less costly than 
either adjuvant RT option. No incremental benefit was seen 
for surveillance in the salvage-free model compared with 
carboplatin given the higher cost associated with surveillance 
in this model (Table 5). In contrast, when ICER analysis 
was performed factoring in the results of our salvage BEP 
reimbursement model, surveillance alone was found to have 
no incremental benefit, to have a higher cost, and to be less 
effective when compared with the other strategies.
Discussion
When evaluating adjuvant strategies for post-orchiectomy 
stage I seminoma patients, the desire to spare as many as 
80%–85% of men further therapy has rapidly been accepted 
as a preferred therapy given a cancer-specific survival 
approaching 100%. Additionally, validation studies have not 
been able to confirm rete testes and testes with a size greater 
than 4 cm as risk factors predicting relapse and necessitating 
the need for adjuvant RT or chemotherapy as opposed to 
surveillance.25,26 Toxicities and risks of second malignancy 
should be noted for each acceptable treatment option, and 
clinicians should understand the high likelihood of salvage 
for such sensitive tumors.19 The desire to highlight these con-
cerns and gain a better understanding of the financial impact 
of therapies led the interest in our hypothetical adjuvant 
model study. Our current model does not include treatment-
related morbidity or patient compliance in the cost analysis. 
Nor are quality of life data available to guide a model for a 
Table 3 Weighted reimbursement model (2011) for each modality factoring in salvage BeP
2011  
Reimbursement








Observation $18,801 0.18 $12,139.00 $20,986.02
Adjuvant Rt
 PA Rt $11,031.00 0.04 $12,139.00 $11,516.56
 Dog-leg Rt $8,908.00 0.04 $12,139.00 $9,393.56
single-cycle carboplatin $19,758.00 0.05 $12,139.00 $20,364.95
Abbreviations: FU, follow-up; BeP, bleomycin, etoposide, cisplatin; PA, para-aortic; Rt, radiation therapy.
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quality-adjusted life year (QALY) analysis, although it would 
be expected that all initial therapies would be tolerated well 
in the acute posttreatment setting.
The descriptive results and hypothetical salvage models 
in this study show that financial savings are expected in 
light of the reduced 2012 follow-up guidelines. The cost 
associated with salvage BEP was the major factor in our 
weighted relapse/salvage models. The small differences in 
cost, especially in light of the young age of these patients 
and expected multiple-decade survival, need to be considered 
critically. The desire to spare 80%–85% of post-orchiectomy 
men further therapy is strong and well founded, especially 
in light of the well described risks of second malignancy 
and toxicities after adjuvant RT.10,27–32 Compared with the 
results of the survey of practicing radiation oncologists by 
Arvold et al,19 the concern regarding the long-term effects of 
salvage chemotherapy may be underestimated in the minds 
of practicing physicians. Kollmannsberger et al,24 in their 
retrospective cohort of 649 patients diagnosed with semi-
noma (545 patients with stage I, 87 patients with stage II, and 
17 patients at stage III disease at diagnosis) reported three 
patient deaths related to chemotherapy (the majority were 
stage II and III patients who were treated either with BEP or 
etoposide and cisplatin). No bleomycin-related hospitaliza-
tions or deaths were reported in their cohort. In addition to a 
non-zero potential salvage chemotherapy mortality rate, van 
den Belt-Dusebout et al33 raised awareness of an increased 
second malignancy risk with salvage chemotherapy. They 
reported a nationwide population-based cohort of testicular 
cancer survivors (n=2,707) treated from 1965 to 1995 in the 
Netherlands evaluating treatment-specific risks of second 
malignancies and cardiovascular disease. Seminoma histol-
ogy represented 1,351 patients in this cohort, and median 
follow-up for the entire cohort was 17.6 years. The second 
malignancy risk with para-aortic RT noted a 2.6-fold increase 
as compared with surgery alone. The second malignancy risk 
associated with chemotherapy (most commonly BEP for 
disseminated seminoma and nonseminoma) was increased 
by 2.1-fold as compared with surgery alone. Major late com-
plications as related to cardiovascular disease were increased 
1.8-fold by RT and 1.9-fold by chemotherapy as compared 
with surgery alone.
Likewise, the late effects of CT imaging follow-up are 
unknown, but have been the source of recent inquiries and 
publications. CT-based imaging in a population of young 
men is associated with a non-zero risk of subsequent cancers 
during patients’ lifetimes as described by Tarin et al.34 Per this 
group, the modeled lifetime cancer risk associated with low-
dose CT exposure was reported to be 1.9% for an 18-year-old 
given 5 years of CT scans per NCCN follow-up guidelines. 
The risk was decreased to 1.2% for a 40-year-old seminoma 
patient per their model calculations. In contrast with the 
above estimates, Pandharipande et al35 looked at the lifetime 
expectancy loss attributable to radiation-induced cancers 
compared with testicular cancer. Modeled radiation-induced 
cancer incidence and mortality risk, in keeping with data from 
BEIR VII,36 from CT surveillance imaging demonstrated a 
life expectancy loss attributable to radiation-induced cancers 
of 24 days, compared with a life expectancy loss attributable 
to stage I testicular cancer for their 33-year-old “base patient” 
of 83 days. The authors concluded that lifetime radiation 
risk estimates, without correcting for the delayed timing of 
radiation-induced cancer risks, can potentially overshadow 
the greater short-term health risk.
It is important to note that a simplified model as pre-
sented here should not be considered evidence for clinical 
Table 5 iceR analysis comparing surveillance (with or without 
factoring in reimbursement for BeP salvage) with alternative 
adjuvant management strategies
ICER analysis  
not factoring  






surveillance versus carboplatin $10,307.69 $–1,831.00
surveillance versus PA-Rt $19,528.57 $–7,318.00
surveillance versus DL-Rt $5,128.57 $–7,010.00
Abbreviations: iceR, incremental cost-effectiveness ratio; BeP, bleomycin, 
etoposide, cisplatin; $–, no incremental benefit for surveillance when compared with 
alternative management strategy; PA, para-aortic; DL, dog-leg; Rt, radiation therapy.
Table 4 Weighted reimbursement model (2012) for each modality factoring in salvage BeP
2012  
Reimbursement








Observation $8,458.00 0.18 $12,139.00 $10,643.02
Adjuvant Rt
 PA Rt $11,192.00 0.04 $12,139.00 $11,677.56
 Dog-leg Rt $9,176.00 0.04 $12,139.00 $9,661.56
single-cycle carboplatin $7,263 0.05 $12,139.00 $7,869.95
Abbreviations: FU, follow-up; BeP, bleomycin, etoposide, cisplatin; PA, para-aortic; Rt, radiation therapy.





decision-making. It is easily argued that our analysis did 
not allow for salvage RT in patients who had initial surveil-
lance or carboplatin and would not necessarily have received 
BEP chemotherapy. Likewise, our model did not account 
for  treatment-related morbidity, second malignancies, or 
pathway-specific quality of life measurements. We also 
contend that picking the appropriate variable for an ICER 
analysis in a model such as ours is difficult. For the purposes 
of our study, the ICER analysis was performed to test one 
parameter, ie, surveillance, against the other adjuvant strate-
gies with an outcome of relapse-free survival. Using surveil-
lance as the parameter seems destined to sway the ICER 
results, given the historically higher relapse rate known in 
patients under surveillance alone. The appropriate variable, 
which we argue is unknown, would need to take into account 
the near 100% cancer-specific survival for these patients, 
the rate and morbidity of acute and chronic toxicities, rate 
of second malignancy (attributable to CT scans, potential 
salvage RT, and BEP salvage chemotherapy) and quality 
of life-specific factors that are so important in a population 
expected to live decades after their initial cancer therapy. 
There is likely very little need for a randomized trial of 
surveillance versus carboplatin versus para-aortic RT given 
what we know today (near 100% cancer-specific survival), 
other than for a prospective collection of morbidity data and 
an instrument to collect quality of life measurements that 
could make analysis such as ours more valuable. We are not 
encouraging such an effort, but rather are using our study 
to highlight the difficulty in predicting the ideal patient out-
come, for a population expected to live for decades, for ICER 
analysis. Availability of more quality-adjusted data in the 
seminoma literature to undertake a $/QALY analysis would 
be of benefit if available from the major Medical Research 
Council trials or surveillance cohort studies.
Highly curable cancers, such as stage I seminoma, are 
excellent cases to study for high-quality outcome tracking 
health care while controlling for cost efficiency. Further 
follow-up and QALY data are needed going forward to avoid 
creating hypothetical cohorts and provide our clinicians with 
more valuable decision-making data. Using our model and 
ICER analysis, para-aortic RT, dog-leg RT, and single-cycle 
carboplatin are cost-effective options for the treatment of stage I 
seminoma patients compared with surveillance alone when 
factoring salvage BEP reimbursement after potential relapse. 
The actual amount of savings identified was smaller than 
expected by our group, and we encourage more robust studies 
to validate these findings. Given the changing health care land-
scape, we are expected to ask these cost and reimbursement 
questions. However, given the small differences seen in our 
study, we might argue that such reimbursement analyses are 
not intended to usurp sound clinical judgment or provide strong 
evidence to avoid a surveillance regimen that could potentially 
spare 80%–85% of patients from additional therapy for such a 
curable malignancy even in the salvage setting; rather, they are 
intended to provide descriptive data and education for health 
care providers with such curable patients and to again remind 
them of the morbidities and potential secondary malignancies 
that can be encountered with adjuvant therapies such as RT 
and chemotherapy.
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